GeneQuantum Healthcare, a leader in ADC (Antibody-Drug Conjugate) new drug development, has entered into a strategic collaboration with BioMap, renowned for its AI in life sciences. This partnership aims to co-develop ADC therapeutics using GeneQuantum’s enzymatic site-specific conjugation technology and BioMap’s AI capabilities. This collaboration is set to redefine the landscape of ADC drug development, focusing on enhancing R&D efficiency, reducing development costs, and advancing high-quality therapeutics to meet global medical needs
English 
German